We are live on ! Find out more
RPTP

Raptor Pharmaceutical
RPTP

Delisted

RPTP was delisted on the 24th of October, 2016.

97 hedge funds and large institutions have $212M invested in Raptor Pharmaceutical in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 34 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

9% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 34

10% less funds holding

Funds holding: 108 → 97 (-11)

38% less capital inflows, than outflows

Capital inflows: $45.7M | Capital outflows: $73.6M

39% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 28

80% less call options, than puts

Call options by funds: $1.22M | Put options by funds: $6.06M

Holders
97
Holders Change
-11
Holders Change %
-10.19%
% of All Funds
2.57%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.08%
New
17
Increased
31
Reduced
34
Closed
28
Calls
$1.22​M
Puts
$6.06​M
Net Calls
-⁠$4.83​M
Net Calls Change
+$1.87​M

RPTP Hedge Fund Activity: Q1 2016 in Review

97 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Raptor Pharmaceutical (RPTP) for Q1 2016, worth a combined $212M — down 19% from $261M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of RPTP and 17 opened new positions — a net loss of 11 holders — while 34 trimmed existing stakes and 31 added.

The largest buyer was Broadfin Capital, adding an estimated $18.4M. The largest seller was Credit Suisse, exiting entirely with an estimated $29.6M sold.

  • 97 institutional investors held Raptor Pharmaceutical (RPTP) as of Q1 2016, down from 108 in Q4 2015.
  • Funds reported $212M of Raptor Pharmaceutical stock for Q1 2016, down 19% quarter-over-quarter.
  • 17 funds opened new Raptor Pharmaceutical positions in Q1 2016 and 28 closed out, a net change of -11 holders.
  • The largest Raptor Pharmaceutical buyer in Q1 2016 was Broadfin Capital, an estimated $18.4M added.
  • The largest Raptor Pharmaceutical seller in Q1 2016 was Credit Suisse, an estimated $29.6M sold.

Based on aggregated 13F filings for Q1 2016.